{
  "guideline": {
    "id": "PA166104992",
    "name": "Annotation of DPWG Guideline for zuclopenthixol and CYP2D6",
    "source": "DPWG",
    "version": 35,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104992",
    "relatedChemicals": [
      {
        "id": "PA452629",
        "name": "zuclopenthixol",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA128",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "symbol": "CYP2D6"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166302908",
      "name": "Recommendation Annotation PA166302908",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA452629",
          "name": "zuclopenthixol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104507,
        "html": "<p>The guideline does not provide a recommendation for zuclopenthixol in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on zuclopenthixol."
      ],
      "lookupKey": {
        "CYP2D6": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302917",
      "name": "Recommendation Annotation PA166302917",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA452629",
          "name": "zuclopenthixol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104516,
        "html": "<p>There is insufficient information available to make a dosage recommendation.</p>\n<ul>\n<li>If the effectiveness is insufficient: try a dose increase. Do not exceed 1.5 times the normal dose.</li>\n</ul>\n"
      },
      "implications": [
        "The risk of ineffectiveness may be elevated. genetic variation leads to an increased conversion of zuclopentixol, which can result in a reduction of the plasma concentration."
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302904",
      "name": "Recommendation Annotation PA166302904",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA452629",
          "name": "zuclopenthixol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104503,
        "html": "<p>Use 75% of the normal dose.</p>\n"
      },
      "implications": [
        "The risk of side effects may be elevated. The genetic variation leads to decreased conversion of zuclopentixol, which causes the plasma concentration to be approximately 1.35-fold higher."
      ],
      "lookupKey": {
        "CYP2D6": "0.75"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302913",
      "name": "Recommendation Annotation PA166302913",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA452629",
          "name": "zuclopenthixol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104512,
        "html": "<p>There is insufficient information available to make a dosage recommendation.</p>\n<ul>\n<li>If the effectiveness is insufficient: try a dose increase. Do not exceed 1.5 times the normal dose.</li>\n</ul>\n"
      },
      "implications": [
        "The risk of ineffectiveness may be elevated. genetic variation leads to an increased conversion of zuclopentixol, which can result in a reduction of the plasma concentration."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302909",
      "name": "Recommendation Annotation PA166302909",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA452629",
          "name": "zuclopenthixol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104508,
        "html": "<p>The guideline does not provide a recommendation for zuclopenthixol in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on zuclopenthixol."
      ],
      "lookupKey": {
        "CYP2D6": "2.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302918",
      "name": "Recommendation Annotation PA166302918",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA452629",
          "name": "zuclopenthixol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104517,
        "html": "<p>There is insufficient information available to make a dosage recommendation.</p>\n<ul>\n<li>If the effectiveness is insufficient: try a dose increase. Do not exceed 1.5 times the normal dose.</li>\n</ul>\n"
      },
      "implications": [
        "The risk of ineffectiveness may be elevated. genetic variation leads to an increased conversion of zuclopentixol, which can result in a reduction of the plasma concentration."
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302905",
      "name": "Recommendation Annotation PA166302905",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA452629",
          "name": "zuclopenthixol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104504,
        "html": "<p>Use 75% of the normal dose.</p>\n"
      },
      "implications": [
        "The risk of side effects may be elevated. The genetic variation leads to decreased conversion of zuclopentixol, which causes the plasma concentration to be approximately 1.35-fold higher."
      ],
      "lookupKey": {
        "CYP2D6": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302914",
      "name": "Recommendation Annotation PA166302914",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA452629",
          "name": "zuclopenthixol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104513,
        "html": "<p>There is insufficient information available to make a dosage recommendation.</p>\n<ul>\n<li>If the effectiveness is insufficient: try a dose increase. Do not exceed 1.5 times the normal dose.</li>\n</ul>\n"
      },
      "implications": [
        "The risk of ineffectiveness may be elevated. genetic variation leads to an increased conversion of zuclopentixol, which can result in a reduction of the plasma concentration."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302901",
      "name": "Recommendation Annotation PA166302901",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA452629",
          "name": "zuclopenthixol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104500,
        "html": "<p>Use 50% of the normal dose.</p>\n"
      },
      "implications": [
        "The risk of side effects may be elevated. The genetic variation results in a decreased conversion of zuclopentixol, which causes the plasma concentration to be approximately 1.6-fold higher."
      ],
      "lookupKey": {
        "CYP2D6": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302910",
      "name": "Recommendation Annotation PA166302910",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA452629",
          "name": "zuclopenthixol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104509,
        "html": "<p>The guideline does not provide a recommendation for zuclopenthixol in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on zuclopenthixol."
      ],
      "lookupKey": {
        "CYP2D6": "2.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302906",
      "name": "Recommendation Annotation PA166302906",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA452629",
          "name": "zuclopenthixol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104505,
        "html": "<p>The guideline does not provide a recommendation for zuclopenthixol in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on zuclopenthixol."
      ],
      "lookupKey": {
        "CYP2D6": "1.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302915",
      "name": "Recommendation Annotation PA166302915",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA452629",
          "name": "zuclopenthixol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104514,
        "html": "<p>There is insufficient information available to make a dosage recommendation.</p>\n<ul>\n<li>If the effectiveness is insufficient: try a dose increase. Do not exceed 1.5 times the normal dose.</li>\n</ul>\n"
      },
      "implications": [
        "The risk of ineffectiveness may be elevated. genetic variation leads to an increased conversion of zuclopentixol, which can result in a reduction of the plasma concentration."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302902",
      "name": "Recommendation Annotation PA166302902",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA452629",
          "name": "zuclopenthixol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104501,
        "html": "<p>Use 75% of the normal dose.</p>\n"
      },
      "implications": [
        "The risk of side effects may be elevated. The genetic variation leads to decreased conversion of zuclopentixol, which causes the plasma concentration to be approximately 1.35-fold higher."
      ],
      "lookupKey": {
        "CYP2D6": "0.25"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302911",
      "name": "Recommendation Annotation PA166302911",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA452629",
          "name": "zuclopenthixol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104510,
        "html": "<p>There is insufficient information available to make a dosage recommendation.</p>\n<ul>\n<li>If the effectiveness is insufficient: try a dose increase. Do not exceed 1.5 times the normal dose.</li>\n</ul>\n"
      },
      "implications": [
        "The risk of ineffectiveness may be elevated. genetic variation leads to an increased conversion of zuclopentixol, which can result in a reduction of the plasma concentration."
      ],
      "lookupKey": {
        "CYP2D6": "3.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302907",
      "name": "Recommendation Annotation PA166302907",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA452629",
          "name": "zuclopenthixol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104506,
        "html": "<p>The guideline does not provide a recommendation for zuclopenthixol in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on zuclopenthixol."
      ],
      "lookupKey": {
        "CYP2D6": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302916",
      "name": "Recommendation Annotation PA166302916",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA452629",
          "name": "zuclopenthixol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104515,
        "html": "<p>There is insufficient information available to make a dosage recommendation.</p>\n<ul>\n<li>If the effectiveness is insufficient: try a dose increase. Do not exceed 1.5 times the normal dose.</li>\n</ul>\n"
      },
      "implications": [
        "The risk of ineffectiveness may be elevated. genetic variation leads to an increased conversion of zuclopentixol, which can result in a reduction of the plasma concentration."
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302903",
      "name": "Recommendation Annotation PA166302903",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA452629",
          "name": "zuclopenthixol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104502,
        "html": "<p>Use 75% of the normal dose.</p>\n"
      },
      "implications": [
        "The risk of side effects may be elevated. The genetic variation leads to decreased conversion of zuclopentixol, which causes the plasma concentration to be approximately 1.35-fold higher."
      ],
      "lookupKey": {
        "CYP2D6": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302912",
      "name": "Recommendation Annotation PA166302912",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA452629",
          "name": "zuclopenthixol",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104511,
        "html": "<p>There is insufficient information available to make a dosage recommendation.</p>\n<ul>\n<li>If the effectiveness is insufficient: try a dose increase. Do not exceed 1.5 times the normal dose.</li>\n</ul>\n"
      },
      "implications": [
        "The risk of ineffectiveness may be elevated. genetic variation leads to an increased conversion of zuclopentixol, which can result in a reduction of the plasma concentration."
      ],
      "lookupKey": {
        "CYP2D6": "4.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "37002327",
      "title": "Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics.",
      "authors": [
        "Beunk Lianne",
        "Nijenhuis Marga",
        "Soree Bianca",
        "de Boer-Veger Nienke J",
        "Buunk Anne-Marie",
        "Guchelaar Henk Jan",
        "Houwink Elisa J F",
        "Risselada Arne",
        "Rongen Gerard A P J M",
        "van Schaik Ron H N",
        "Swen Jesse J",
        "Touw Daan",
        "van Westrhenen Roos",
        "Deneer Vera H M",
        "van der Weide Jan"
      ],
      "journal": "European journal of human genetics : EJHG",
      "year": 2024
    },
    {
      "pmid": "21412232",
      "title": "Pharmacogenetics: from bench to byte--an update of guidelines.",
      "authors": [
        "Swen J J",
        "Nijenhuis M",
        "de Boer A",
        "Grandia L",
        "Maitland-van der Zee A H",
        "Mulder H",
        "Rongen G A P J M",
        "van Schaik R H N",
        "Schalekamp T",
        "Touw D J",
        "van der Weide J",
        "Wilffert B",
        "Deneer V H M",
        "Guchelaar H-J"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2011
    }
  ],
  "version": "2024-03-25-16-13"
}